person · Reporting owner

York Charles N II

Disclosed activity across 2 companies

Tapewire entity: 51459
SEC CIK: 0001655962

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Spyre Therapeutics, Inc.AGLE · Entity 2649	Chief Financial Officer and VP	February 14, 2020	February 19, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Spyre Therapeutics, Inc.

Report date February 14, 2020 · Filed February 19, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2030-02-13	Direct	126,000	Reported balance After 2020-02-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-02-14 · Grant · Acquired 126,000 · Balance 126,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Day One Biopharmaceuticals, Inc.

Report date April 23, 2026 · Filed April 23, 2026

Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-23 transaction · row 1 1 source row Row 1 · 2026-04-23 · Disposition to issuer · Disposed 312,025 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25	Direct	Reported balance After 2026-04-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-23 · Disposition to issuer · Disposed 497,667 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-01-17	Direct	Reported balance After 2026-04-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-23 · Disposition to issuer · Disposed 151,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-01-16	Direct	Reported balance After 2026-04-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-23 · Disposition to issuer · Disposed 116,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-01-04	Direct	Reported balance After 2026-04-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-23 · Disposition to issuer · Disposed 162,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2035-01-14	Direct	Reported balance After 2026-04-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-23 · Disposition to issuer · Disposed 162,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2036-01-29	Direct	Reported balance After 2026-04-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-23 · Disposition to issuer · Disposed 188,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F9: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-23 · Disposition to issuer · Disposed 6,750 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-23 · Disposition to issuer · Disposed 46,375 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-23 · Disposition to issuer · Disposed 72,875 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-04-23 · Disposition to issuer · Disposed 118,125 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F13: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

Filing footnotes · ownership attribution and instrument terms

F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F3: The options are fully vested.

F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F5: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F6: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F7: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F8: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F9: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

F13: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 16, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	4,282	$6.26	$26,796.33	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · nonDerivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,231 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.19 to $6.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document
May 15, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	6,625	$0.00	$0.00	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · derivative · entry 9 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,750 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
May 15, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	6,625	$0.00	$0.00	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · derivative · entry 8 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,250 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
May 15, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
May 15, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,375	$0.00	$0.00	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
May 15, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	6,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 15, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	6,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 15, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 15, 2025 Filed May 19, 2025 21:45 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	1,375	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-013679 · form4-05192025_090554.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 18, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	4,370	$11.96	$52,278.31	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · nonDerivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,638 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.86 to $12.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document
February 15, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	6,625	$0.00	$0.00	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · derivative · entry 9 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,375 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	6,625	$0.00	$0.00	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · derivative · entry 8 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,875 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,375	$0.00	$0.00	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,125 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
February 15, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	6,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	6,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2025 Filed Feb 21, 2025 23:10 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	1,375	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-005159 · form4-02212025_110259.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
January 15, 2025 Filed Jan 31, 2025 21:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantRestricted Stock Units · Derivative	106,000	$0.00	$0.00	Disclosure SEC source: 0001415889-25-002497 · form4-01312025_090118.xml · derivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 106,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
January 15, 2025 Filed Jan 31, 2025 21:38 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	GrantStock Option (right to buy Common Stock) · Derivative	162,000	$0.00 Strike: $11.87	$0.00	Disclosure SEC source: 0001415889-25-002497 · form4-01312025_090118.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 162,000 shares Expires 2035-01-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 18, 2024 Filed Nov 19, 2024 21:30 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	2,602	$13.21	$34,372.94	Disclosure SEC source: 0001415889-24-027224 · form4-11192024_091114.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,133 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $13.02 to $13.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:30 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	6,625	$0.00	$0.00	Disclosure SEC source: 0001415889-24-027224 · form4-11192024_091114.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:30 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001415889-24-027224 · form4-11192024_091114.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:30 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,375	$0.00	$0.00	Disclosure SEC source: 0001415889-24-027224 · form4-11192024_091114.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:30 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	6,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027224 · form4-11192024_091114.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:30 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027224 · form4-11192024_091114.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:30 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	1,375	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027224 · form4-11192024_091114.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 16, 2024 Filed Aug 19, 2024 22:07 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	2,633	$14.00	$36,859.63	Disclosure SEC source: 0001415889-24-021626 · form4-08192024_100802.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,485 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document
August 15, 2024 Filed Aug 19, 2024 22:07 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	6,625	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021626 · form4-08192024_100802.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,125 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
August 15, 2024 Filed Aug 19, 2024 22:07 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021626 · form4-08192024_100802.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
August 15, 2024 Filed Aug 19, 2024 22:07 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,375	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021626 · form4-08192024_100802.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,875 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
August 15, 2024 Filed Aug 19, 2024 22:07 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	6,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-021626 · form4-08192024_100802.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 15, 2024 Filed Aug 19, 2024 22:07 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-021626 · form4-08192024_100802.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
August 15, 2024 Filed Aug 19, 2024 22:07 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	1,375	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-021626 · form4-08192024_100802.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 16, 2024 Filed May 17, 2024 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	2,675	$16.08	$43,010.52	Disclosure SEC source: 0001415889-24-013616 · form4-05172024_100532.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,868 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document
May 15, 2024 Filed May 17, 2024 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	6,625	$0.00	$0.00	Disclosure SEC source: 0001415889-24-013616 · form4-05172024_100532.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,750 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 15, 2024 Filed May 17, 2024 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001415889-24-013616 · form4-05172024_100532.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 15, 2024 Filed May 17, 2024 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,375	$0.00	$0.00	Disclosure SEC source: 0001415889-24-013616 · form4-05172024_100532.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 15, 2024 Filed May 17, 2024 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	6,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-013616 · form4-05172024_100532.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 15, 2024 Filed May 17, 2024 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-013616 · form4-05172024_100532.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 15, 2024 Filed May 17, 2024 22:15 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	1,375	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-013616 · form4-05172024_100532.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
May 03, 2024 Filed May 3, 2024 22:44 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	8,078	$17.85	$144,214.11	Disclosure SEC source: 0001415889-24-012253 · form4-05032024_100559.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,293 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 6, 2023. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $17.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 02, 2024 Filed May 3, 2024 22:44 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	200	$17.90	$3,579.10	Disclosure SEC source: 0001415889-24-012253 · form4-05032024_100559.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,371 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 6, 2023. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.85 to $17.955 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 01, 2024 Filed May 3, 2024 22:44 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	52,183	$17.89	$933,397.32	Disclosure SEC source: 0001415889-24-012253 · form4-05032024_100559.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,571 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 6, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $18.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 16, 2024 Filed Feb 20, 2024 23:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	SaleCommon Stock	2,666	$15.25	$40,651.43	Disclosure SEC source: 0001415889-24-004469 · form4-02202024_110257.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,754 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	6,625	$0.00	$0.00	Disclosure SEC source: 0001415889-24-004469 · form4-02202024_110257.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,375 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001415889-24-004469 · form4-02202024_110257.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,750 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	1,375	$0.00	$0.00	Disclosure SEC source: 0001415889-24-004469 · form4-02202024_110257.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,625 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	6,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-004469 · form4-02202024_110257.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document
February 15, 2024 Filed Feb 20, 2024 23:36 UTC	Day One Biopharmaceuticals, Inc. DAWN · Entity 51180	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-004469 · form4-02202024_110257.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.